Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARTAGNAN: Nebulized Amikacin for Ventilator-Associated Pneumonia
NCT00861315Phase 3Unknown
- Sponsor
- Association pour la Promotion à Tours de la Réanimation Médicale
- Start
- Jan 2009
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amikacin in ventilator-associated pneumonia (VAP), sponsored by Association pour la Promotion à Tours de la Réanimation Médicale. Primary endpoint: Serum amikacin concentration at 24 hours. Status: unknown.
02
Drugs
amikacin
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT00861315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00861315.